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S12Objective: The emergence of transcatheter approaches to mitral valve (MV) repair has focused attention on out-
comes after surgical MV repair. Results from the EVEREST II trial demonstrated worse short-term major ad-
verse event (MAE) rates for surgical repair. This study analyzes contemporary outcomes of surgical MV repair
to establish a benchmark for future therapeutic comparisons.
Methods: From 2003 to 2008, 903 isolated MV repair operations were performed at 13 different statewide car-
diac centers. Patients were excluded if they had prior valve operations or mitral stenosis similar to EVEREST II.
MAE rate was defined using similar criteria to EVEREST II, including postoperative atrial fibrillation and trans-
fusion of 2 units of blood or more. Univariate analyses and multivariate regression models were applied to iden-
tify independent predictors of MAEs after surgical MV repair.
Results:Mean patient age was 57.0 13.2 years, and the majority of patients were men (59.0%, 533/903). The
prevalence of preoperative risk factors was as follows: stroke 3.9% (35/903), immunosuppression 2.4% (22/
903), heart failure 32.1% (290/903), renal failure 3.5% (32/903), and previous coronary artery bypass grafting
3.4% (31/903). Mean ejection fraction was 55.6  11.3%. MAE rate was 29.0% (262/903), including atrial
fibrillation 17.6% (159/903), renal failure 1.3% (12/903), stroke 0.9% (8/903), and operative mortality
1.1% (10/903). Multivariate correlates ofMAE included the following: advanced age, prior stroke, immunosup-
pression, and operation time. Importantly, gender, previous coronary bypass grafting, renal failure, and ejection
fraction were not independent predictors of MAE.
Conclusions: In the current era, patients undergoing surgical MV repair have low mortality. MAE rate was
largely due to postoperative atrial fibrillation. These results may help to stratify which patients may be best
served with newer technologies. (J Thorac Cardiovasc Surg 2012;143:S12-6)It is generally accepted thatmitral valve (MV) repair is thepre-
ferred surgical approach for patients with severe mitral regur-
gitation (MR).1-4 MV repair has several intrinsic advantages
over bioprosthetic or mechanical valve replacement, and
the efficacy of MV repair has been demonstrated for
both degenerative and ischemic MVetiology.5,6
The recent emergence of transcatheter approaches to MV
repair has extended treatment options for patients with sig-
nificant MR. However, the durability of such approaches
has yet to be widely established. In the recently published
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The Journal of Thoracic and Cardiovascular Surgin a 2:1 ratio to receive either percutaneous or surgical treat-
ment for 3 to 4þmitral insufficiency.7 The goal of the trial
was to determine the safety and efficacy of each treatment
approach by examining differences in composite end points.
In the assessment of safety, the primary end point was the
composite incidence of major adverse events (MAEs),
and the authors reported improved safety for percutaneous
repair with an MAE rate of 15% compared with 48%
with surgical treatment. However, criticism of these com-
parisons has arisen owing to the large influence that packed
red blood cell (PRBC) transfusion rates exerted on theMAE
composite end point, and when transfusion rates were not
considered in the MAE analysis, no significant differences
existed in safety between percutaneous and surgical
treatment.
In light of these reported results, the objective of this
study was to examine contemporary outcomes for surgical
MV repair within a multi-institutional cohort of patients
to establish a more accurate benchmark for future therapeu-
tic comparisons.PATIENTS AND METHODS
Patients
This study was exempt from University of Virginia Institutional Review
Board review. Deidentified patient records were obtained from the Virginiaery c April 2012
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CI ¼ confidence interval
MAE ¼ major adverse event
MR ¼ mitral regurgitation
MV ¼ mitral valve
OR ¼ odds ratio
PRBC ¼ packed red blood cell
STS ¼ The Society of Thoracic Surgeons
VCSQI ¼ Virginia Cardiac Surgery Quality
Initiative (database)Cardiac Surgery Quality Initiative (VCSQI) database. The VCSQI is a vol-
untary consortium of 16 different statewide cardiac centers that captures
approximately 99% of all cardiac procedures within the commonwealth
of Virginia. Each VCSQI center contributes its data to The Society of Tho-
racic Surgeons (STS) Adult Cardiac Database. This secondary analysis of
the VCSQI database retrospectively reviewed all patients undergoing iso-
lated MV repair procedures from January 2003 to December 2008. To pro-
vide a similar estimate of outcomes to those reported in the EVEREST II
trial, we excluded patients with rheumatic heart disease, mitral stenosis,
and prior endocarditis.
Patient risk factors, operative features, postoperative complications, and
total hospital length of stay were evaluated. Established STS definitions for
all analyzed variables were used. Operative mortality included patient
deaths that occurred before hospital discharge or within 30 days of opera-
tion. Similar to EVEREST II, the composite outcome of MAEs included
the following: death, stroke, reoperation for valve dysfunction, urgent/
emergency reoperation, perioperative myocardial infarction, renal failure,
deep sternal wound infection, prolonged mechanical ventilation (>24
hours), new-onset atrial fibrillation, sepsis, gastrointestinal complication,
and total (intraoperative and postoperative) transfusion of 2 units of PRBCs
or more.
Statistical Analysis
The primary outcomes of interest were MAE rate and the identification
of independent predictors of MAE. Secondary outcomes included the inci-
dence of individual postoperative complications, operative mortality, and
postoperative length of stay. Continuous variables are reported as mean
 standard deviation, and categorical variables are expressed as percentage
of the total study population. Univariate analyses for the outcome of MAE
included c2 or Fisher’s exact test for categorical variable comparisons,
whereas single-factor analysis of variance was used to compare continuous
data.
Multiple logistic regression was used to identify independent predictors
of MAE after adjusting for the confounding influence of various patient-
and operation-related risk factors. All preoperative variables entered as co-
variates were selected a priori on the basis of established clinical risk for
MV operations. Odds ratios (ORs) with a 95% confidence interval (CI)
are used to report the results of logistic regression modeling. Model perfor-
mance was assessed by the Hosmer-Lemeshow goodness of fit test and by
evaluating the area under the receiver operating characteristics curve. Re-
ported P values are 2-tailed. Data manipulation and analysis were per-
formed using Predictive Analytics SoftWare, version 18 (IBM
Corporation, Somers, NY).
RESULTS
Patient Characteristics and Operative Features
A total of 903 patients underwent MV repair and met
study inclusion and exclusion criteria during the 5-yearThe Journal of Thoracic and Carstudy period. The overall MV repair rate for all study cen-
ters was 53.3% during the study period, and the rate of
MV repair differed as a function of hospital procedure
volume. MV repair rate was 65.9% for the highest vol-
ume center during the study period and 29.6% for the
lowest volume center during the study period. Mean pa-
tient age was 57 years, and women accounted for
41.0% of all patients. The prevalence of major comorbid
disease included stroke (3.9%), diabetes (9.1%), heart
failure (32.1%), and renal failure (3.5%). Mean ejection
fraction was 55.6%. Moderate (12.5%) and severe
(81.7%) MR accounted for the majority of cases. Previ-
ous coronary artery bypass grafting occurred in 3.4% of
patients. The majority of cases were elective MV repair
(85.2%) and consisted of MV reconstruction with annulo-
plasty (68.9%).Incidence of Postoperative Outcomes After Surgical
MV Repair
Themost common postoperative complications (Figure 1)
included atrial fibrillation (17.6%), transfusion of 2 units
of PRBCs or more (8.6%), prolonged mechanical ventila-
tion (4.5%), reoperation for bleeding/tamponade (3.5%),
and renal failure (1.3%). Operative mortality was 1.1%.
The composite MAE rate was 29.0% and decreased to
13.8% when the influence of postoperative atrial fibrilla-
tion was removed. The average postoperative length of
stay was 6.1  4.6 days.Univariate and Multivariate Correlates of MAEs
To identify univariate correlates of MAEs, we stratified
patient data by the outcome of MAE. Patient factors found
to be significantly associated with the incidence of MAE
included the following: increased patient age (P< .001),
female gender (P ¼ .04), presence of cerebrovascular dis-
ease (P ¼ .002), preoperative stroke (P<.001), immuno-
suppressive therapy use (P<.001), history of angina (P ¼
.02), heart failure (P < .001), preoperative arrhythmia
(P< .001), advanced New York Heart Association class
(P<.001), renal failure (P ¼ .02), and declining ejection
fraction (P ¼ .004). The performance of urgent/emergency
operations (P<.001) as well as MV repair with either annu-
loplasty alone (P<.001) or an MV reconstruction without
annuloplasty (P<.001) were significant operation-related
correlates of MAE. On multiple logistic regression
(Table 1), only patient age, preoperative stroke, and immu-
nosuppressive therapy use were statistically associated with
the composite MAE outcome. Importantly, female gender,
renal failure, history of coronary artery bypass grafting,
and preoperative ejection fraction had no significant associ-
ation with MAE. The predictive model proved to be an
adequate performer with a Hosmer-Lemeshow P ¼ .07
and an area under the curve ¼ 0.82.diovascular Surgery c Volume 143, Number 4S S13
FIGURE 1. Incidence of postoperative complications. MAE, Major adverse event rate; AF, atrial fibrillation; PRBC, packed red blood cells; RF, renal
failure.
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The present study provides a generalizable report of con-
temporary postoperative outcomes after surgical MV repair
within a multi-institutional cohort of 903 patients who were
operated on by both high- and low-volume mitral surgeons
at 16 different statewide centers. Despite surgeon volumes,
however, surgical MV repair was associated with low oper-
ative mortality and acceptable morbidity. Using similar in-
clusion and exclusion criteria to that of the EVEREST II
trial, we have provided an alternative report of postopera-
tive outcomes to establish a benchmark on which to base fu-
ture therapeutic comparisons. The definition of MAE rate inTABLE 1. Multivariable logistic regression results for the outcome of
MAEs among patients undergoing isolated MV repair operations (n¼
903)
Covariate OR 95% CI P value
Age 1.046 1.029-1.063 <.001
Stroke 3.206 1.244-8.263 .02
Immunosuppressive therapy 9.958 2.286-43.379 .002
Gender (female) 1.266 0.875-1.830 .21
Peripheral vascular disease 0.712 0.273-1.860 .49
Diabetes 0.733 0.371-1.449 .37
Dyslipidemia 1.029 0.695-1.523 .89
Hypertension 1.022 0.707-1.478 .91
Renal failure 0.896 0.123-6.556 .91
Hemodialysis 1.800 0.164-19.751 .63
Previous CABG 0.983 0.298-3.247 .98
Angina 1.801 0.856-3.789 .12
Arrhythmia 0.757 0.411-1.394 .37
NYHA III 1.234 0.806-1.889 .33
NYHA IV 1.512 0.548-4.175 .43
Heart failure 1.063 0.681-1.660 .79
Urgent/emergency status 0.000 0.000-0.000 .99
IABP 4.228 0.332-53.900 .27
Ejection fraction (%) 0.985 0.968-1.003 .1
Model performance: Area under receiver operator curve ¼ 0.82. P values in bold are
statistically significant.MAE, Major adverse event;MV, mitral valve; OR, odds ratio;
CI, confidence interval; CABG, coronary artery bypass grafting; NHYA, New York
Heart Association; IABP, intra-aortic balloon pump.
S14 The Journal of Thoracic and Cardiovascular Surgthe present report is similar to that used in EVEREST II.
However, the composite incidence of MAE is this series
(29%) proved to be substantially lower than that reported
for the surgical arm in EVEREST II (48%). More impor-
tant, postoperative atrial fibrillation largely influenced the
incidence of MAE in our series. In addition, we identified
important univariate and multivariate correlates of MAE
to further identify at-risk patient populations undergoing
surgical MV repair, including advanced patient age, stroke,
and preoperative immunosuppressive therapy use. These re-
sults not only serve to provide a generalizable report of cur-
rent MV repair outcomes but also extend the discussion of
important discrepancies that may exist between investiga-
tions designed to assess the comparative effectiveness of
emerging MV repair technology.
The results of the present study are in agreement with
other recent surgical series. The 1.1% operative mortality
rate compares favorably with nationwide mortality rates
for MV repair of approximately 1.4% to 1.5%.8,9 In
addition, we report a slightly lower incidence of need for
reoperation, postoperative stroke rates, and new-onset he-
modialysis requirements compared with other recent esti-
mates.9 The average postoperative length of stay of 6 days
after MV repair is also similar to that reported by Gammie
and colleagues9 in their recent review of nationwide out-
comes. Perhaps even more important, however, is that these
outcomes compare favorably with recently reported results
comparing percutaneous MV repair with surgical repair or
replacement.
Earlier this year, Feldman and colleagues7 published the
results of the EVEREST II trial and reported improved
safety of percutaneous repair. In their analysis, MAE oc-
curred in 15% of percutaneously treated patients compared
with 48% of surgically treated patients. Important to con-
sider in these results was the inclusion of both MV repair
and replacement operations in the surgical arm of this trial
and the fact that worse outcomes after MV replacement
have been well documented in prior studies.2,3,6ery c April 2012
TABLE 2. MAE rate for percutaneous and surgical arms of









Overall 9.6% 57.0% 29.0%
Death 0.0% 2.5% 1.1%
Myocardial infarction 0.0% 0.0% 0.0%
Reoperation for surgical failure 0.0% 1.3% 0.0%
Urgent or emergency surgery
for adverse event*
0.0% 5.1% 3.5%
Stroke 0.0% 2.5% 0.0%
Renal failure 0.0% 0.0% 1.3%
Deep wound infection 0.0% 0.0% 0.0%
Prolonged ventilationy 0.0% 5.1% 4.5%
GI complication 0.7% 0.0% 0.0%
Atrial fibrillationz 0.0% 0.0% 17.6%
Sepsis 0.0% 0.0% 0.0%
Transfusion>2 units of blood 8.8% 53.2% 8.6%
MAE, Major adverse event; MV, mitral valve; GI, gastrointestinal. *Rate of reopera-
tion for bleeding for surgical MV repair patients. yProlonged ventilation (mechanical
ventilation>48 hours for EVEREST II and>24 hours for surgical MV repair). zAtrial
fibrillation: New onset of persistent atrial fibrillation for EVEREST II.
LaPar et al Mitral Valve ProlapseFurthermore, in the overall assessment of the composite
incidence of MAE in EVEREST II, the disproportionate
outcomes between the percutaneous and surgical arms
was largely influenced by the higher rate of PRBC
transfusion after surgical treatment. As a result, once
this factor was eliminated from analysis, the composite
MAEs were no longer significantly different between
percutaneous and surgical treatment of mitral insufficiency.
In light of these findings, the most significant results of
the present study were the significantly lower composite
MAE rate for isolated, surgical MV repair (29.0%) com-
pared with that reported in the surgical arm of EVEREST
II (Table 2). Other striking differences between the present
series and that reported in EVEREST II were the signifi-
cantly lower total PRBC transfusion rate (8.6%), stroke
rate (0.9%), reoperation rate for valve dysfunction
(0.3%), and mortality rate (1.1%). Unlike that observed
in EVEREST II, we noticed that the composite MAE rate
in this series was largely influenced by postoperative atrial
fibrillation and not dominated by transfusion differences.
This is likely due to a difference in definition of atrial fibril-
lation. EVEREST II reported the incidence of permanent
atrial fibrillation, whereas in our series atrial fibrillation
used the STS definition, which is simply the presence of
new-onset postoperative atrial fibrillation irrespective of
persistent atrial fibrillation. When we removed this compli-
cation from the analysis of MAE, the composite incidence
dropped to 13.8%. In the present series the 8.6% rate of sig-
nificant PRBC transfusion included both intraoperative and
postoperative transfusions, which may explain the discor-
dance with the lower incidence for reoperation for bleeding
(3.5%). More important, however, the incidence of majorThe Journal of Thoracic and Cartransfusion was much lower than that reported for the surgi-
cal arm in EVEREST II (53.2%) and compares favorably
with the 8.8% rate for the percutaneous arm.
To further stratify which patients may be more or less
likely to encounter MAE after surgical MV repair, we
identified patient- and operation-related factors that had
significant univariate and multivariate associations with
the onset of MAE. As a result, advanced patient age by
year was associated with a 4.6% increase in the odds of
encountering an MAE after surgical MV repair, whereas
preoperative stroke and history of immunosuppressive
therapy were associated with a 3.2-fold and 9.9-fold in-
crease in the odds of MAE. These results are important
in an era of increasing emphasis on individual patient
risk stratification and suggest that patients with these risk
factors should be considered for novel MV therapies if
they prove durable.
This study has limitations. The retrospective study de-
sign introduces inherent selection bias, while the influence
of surgeon selection for MV repair versus replacement
cannot be accounted for and may have influenced the re-
ported results. The use of established STS definitions for
all examined variables, differences in the definitions of
certain adverse events (ie, prolonged ventilation, postoper-
ative atrial fibrillation), as well as the presence of com-
pletely deidentified data limited the ability to provide
exact comparisons with other trials, including the EVER-
EST II. In addition, the reported results may not be extrap-
olated to MV replacement outcomes and may, thus, be of
limited utility to centers with low MV repair rates. Certain
data, including valve morphology or etiology, could not be
analyzed, and long-term follow-up would add impact to
the reported results. Nevertheless, the markedly improved
outcomes after MV repair reported in this series provide
an important clinical contribution inasmuch as they high-
light contemporary trends within a multi-institutional co-
hort of patients that are highly generalizable to patients
undergoing treatment for moderate to severe mitral
insufficiency.CONCLUSIONS
On the basis of the reported results, patients undergoing
surgical MV repair have low mortality and acceptable mor-
bidity. Composite MAE rate was largely influenced by post-
operative atrial fibrillation. These results compare favorably
with recently reported trials examining both percutaneous
and surgical treatment approaches to mitral insufficiency
and may help to stratify which patients may be best served
with newer technologies.References
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